Paul Campanelli - Endo International Insider

ENDP -- USA Stock  

USD 11.21  0.38  3.51%

President CEO, Director
Mr. Paul V. Campanelli serve as President, Chief Executive Officer, Director of the Company. Mr. Campanelli joined Endo in 2015 as the President of Par Pharmaceutical, leading Endos fully integrated U.S. Generics business, following Endos acquisition of Par Pharmaceutical. Prior to joining Endo, he had served as Chief Executive Officer of Par Pharmaceutical Companies, Inc. following the companys September 2012 acquisition by TPG. While CEO of Par, Mr. Campanelli built a strong leadership team and an industryleading generics business. Under his leadership, the company significantly increased total revenue, acquired Michiganbased JHP Pharmaceuticals, established a business office in London to serve as Pars entry point into the European generics market and completed its acquisition of an active pharmaceutical ingredients facility located in Chennai, India. Prior to the TPG acquisition, Mr. Campanelli served as Chief Operating Officer and President of Par Pharmaceutical, Inc., the companys generics division, from 2011 to 2012. Earlier in his tenure at Par, Mr. Campanelli held roles of increasing responsibility, including Senior Vice President, Business Development Licensing Executive Vice President and President of Par Pharmaceutical, Inc. and was named a Corporationrationrate Officer by Pars board of directors. He also served on the board of directors of Sky Growth Holdings Corporationrationration. Prior to joining Par, Mr. Campanelli served as Vice President, Business Development at Dr. Reddys Laboratories Ltd. where he was employed from 19922001
Age: 55  CEO Since 2016      
353 1 268 2000
Campanelli earned his BS degree from Springfield College.

Paul Campanelli Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 3.03 % which means that it generated profit of $3.03 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of (143.52) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 8.27 B in liabilities. Endo International plc has Current Ratio of 1.04 suggesting that it is not liquid enough and may have problems to pay out its financial obligations when they are due.

Similar Executives

Entity Summary

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. Endo International operates under Drug Manufacturers - Specialty Generic classification in USA and traded on NASDAQ. It employs 30 people.Endo International plc (ENDP) is traded on BATS Exchange in USA. It is located in IRELAND and employs 3,039 people. Endo International is listed under Pharmaceutical Products category by Fama And French industry classification.

Endo International plc Leadership Team

Carrie Nichol, President, MBA
William Spengler, Director
Arthur Higgins, Director
Brian Lortie, President
Donald DeGolyer, CEO
William Montague, Director
Michael Hyatt, Director
Douglas Ingram, Director
Antonio Pera, President, MBA
Roger Kimmel, Chairman
Susan Hall, EVP, Ph.D
Sharad Mansukani, Director
Suketu Upadhyay, CFO, CPA
Nancy Hutson, Director
Todd Sisitsky, Director, MBA
Patrick Barry, President, MBA
Shane Cooke, Director
Craig Paterson, Executive, MBA
Daniel Rudio, President
Camille Farhat, President, MBA
Paul Campanelli, CEO
Jill Smith, Director
Rajiv Silva, CEO
Nina Goworek, Director
Blaise Coleman, President, MBA
Terrance Coughlin, President
Matthew Maletta, President

Stock Performance Indicators

Did you try this?

Run Premium Stories Now

Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
All  Next Launch Premium Stories

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Endo International and Diplomat Pharmacy. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.